COHBAR INC - CWBR STOCK NEWS

CohBar, Inc. (NASDAQ: CWBR) has signed a Non-Clinical Evaluation Agreement with the National Institute of Allergy and Infectious Diseases to evaluate CB5064 Analogs for treating COVID-19 associated Acute Respiratory Distress Syndrome (ARDS). Positive results in models of acute lung injury were noted, including reduced fluid accumulation and neutrophil infiltration. The agreement involves testing in preclinical models, specifically the golden Syrian hamster model. This collaboration is part of CohBar's strategy to develop mitochondria-based therapeutics aimed at chronic diseases.

CohBar, a clinical-stage biotechnology company, announced promising preclinical data on its apelin agonist peptides, indicating efficacy in treating acute respiratory distress syndrome (ARDS), including COVID-19 associated ARDS. The study demonstrated that CB5064 Analog significantly reduced lung fluid accumulation and pro-inflammatory cytokines in a mouse model. This represents a potential breakthrough for the estimated three million patients globally suffering from ARDS. CohBar plans to continue studies and present findings at a future conference.

On November 19, 2020, CohBar, Inc. (NASDAQ: CWBR) announced that CEO Steven Engle will present a company overview at the virtual Piper Sandler 32nd Annual Healthcare Conference from December 1-3, 2020. The presentation will be available on demand for registered attendees.

CohBar specializes in developing mitochondria-based therapeutics for chronic diseases. Their lead compound, CB4211, is currently in Phase 1b trials for NASH and obesity, alongside four preclinical programs targeting various diseases, including COVID-19 associated ARDS.

CohBar (NASDAQ: CWBR) announced its third-quarter 2020 financial results, highlighting a cash position of $23.4 million as of September 30, compared to $12.6 million at the end of 2019. The company raised $15 million to fund its R&D pipeline and has completed dosing in half of the subjects for its Phase 1b study evaluating CB4211 for NASH and obesity. Expected top-line data for this study is anticipated in Q2 2021. Additionally, promising data was reported for the CB5138 Analog in treating Idiopathic Pulmonary Fibrosis.

CohBar (NASDAQ: CWBR) plans to release its Q3 2020 financial results after market close on November 16, 2020. A conference call with a slide presentation will follow at 5:00 p.m. ET. Participants can access the call via U.S. or international dial-in numbers provided in the release. CohBar focuses on developing mitochondria-based therapeutics for chronic diseases and has entered Phase 1b trials for its lead compound, CB4211, targeting NASH and obesity. The company has discovered over 100 mitochondrial-derived peptides, with multiple preclinical programs underway.

CohBar, Inc. (NASDAQ: CWBR) announced a KOL webinar on November 6, 2020, focusing on idiopathic pulmonary fibrosis (IPF) treatment and preclinical findings of CB5138 Analogs. The session will feature Dr. Toby Maher discussing IPF's treatment landscape and unmet needs, followed by a Q&A. CohBar will present data showcasing enhanced effects of combining CB5138 Analog with nintedanib in reducing fibrosis and inflammation compared to nintedanib alone. CohBar specializes in mitochondria-based therapeutics for chronic diseases aiming to address significant medical needs.

CohBar, Inc. (NASDAQ: CWBR) will present at the ROTH Capital COVID-19 Therapeutics in Development Event on October 28, 2020. CEO Steven Engle and CSO Dr. Kenneth Cundy will discuss therapies for COVID-19, focusing on CB5064 Analogs, which may alleviate acute respiratory distress syndrome (ARDS) caused by COVID-19. These analogs show promising results in reducing fluid accumulation and inflammatory responses in preclinical models. CohBar’s innovative approach involves developing mitochondria-based therapeutics targeting chronic diseases and age-related conditions.

CohBar, Inc. (NASDAQ: CWBR) is set to host a Key Opinion Leader webinar on November 6, 2020, at 2:00 PM ET, focusing on the treatment landscape for Idiopathic Pulmonary Fibrosis (IPF) and the promising findings from preclinical studies of its CB5138 Analogs. Recent preclinical data show that a combination of CB5138-2 and the standard IPF treatment nintedanib resulted in greater reductions in fibrosis and inflammation in mice compared to nintedanib alone. This suggests that CohBar's peptides may effectively enhance existing treatments for IPF.

CohBar, Inc. (NASDAQ: CWBR) announced on October 15, 2020, that CEO Steven Engle will present a company update at the virtual BIO-Europe Conference from October 26-29, 2020. This conference, attracting over 3,000 attendees from 50+ countries, will feature key industry figures from biotech and pharmaceutical sectors. CohBar specializes in mitochondria-based therapeutics aimed at treating chronic diseases and extending healthy lifespan, with its lead compound, CB4211, currently in a Phase 1b clinical trial for NASH and obesity.